For decades, Alzheimer’s disease has seemed like one of medicine’s most stubborn enemies.
Cancer treatments improved. Heart disease became more preventable. Hepatitis C went from a lifelong infection to something medicine can often cure.
But Alzheimer’s?
For millions of families, the answer seemed to remain the same:
We can diagnose it. We can manage some symptoms. But we cannot stop it.
That is beginning to change.
Not enough to declare victory. Not enough to say Alzheimer’s has been cured. But enough that we should probably stop saying that nothing can be done.
The important question now is not whether there has been progress.
There has.
The question is:
How much of that progress is meaningful—and how much is hope getting ahead of the science?
The most accurate answer is somewhere in the middle.
Alzheimer’s Medicine Has Crossed an Important Line
Until recently, most Alzheimer’s medications were designed primarily to help symptoms.
They might temporarily improve memory, thinking or daily functioning in some patients, but they did not substantially alter the underlying disease process.
That changed with drugs such as Leqembi, or lecanemab, and Kisunla, or donanemab.
These medications target beta-amyloid, a protein that can accumulate in the brains of people with Alzheimer’s disease.
Leqembi received traditional FDA approval in 2023 after a clinical trial found that it removed amyloid and produced moderately less cognitive and functional decline over 18 months than placebo.
Kisunla followed in 2024. The FDA approved it for people with early symptomatic Alzheimer’s disease—the mild cognitive impairment or mild dementia stages in which it had been studied.
That’s an important distinction.
These drugs don’t simply treat symptoms.
They attempt to modify part of the biological process associated with Alzheimer’s disease.
That is genuine progress.
But this is where the headlines sometimes run ahead of reality.
Slowing Alzheimer’s Is Not the Same as Stopping It
Imagine two cars rolling downhill.
One is traveling 40 miles per hour.
The other is traveling 30.
The slower car is doing better—but both are still going downhill.
That’s roughly how we should think about today’s disease-modifying Alzheimer’s treatments.
They may slow cognitive decline in appropriately selected patients, but they have not been shown to restore the brain to normal or make established Alzheimer’s disappear.
That may sound disappointing.
I look at it differently.
Slowing decline could potentially mean additional months of independence, conversation, recognition, decision-making and ordinary life.
For an Alzheimer’s patient and family, those aren’t trivial outcomes.
But we shouldn’t turn “slower decline” into “Alzheimer’s breakthrough cure.”
It isn’t.
Not yet.
That distinction is central to the way we discuss future medicine at Elderhood.
We can be optimistic without becoming gullible.
The Safety Problem Cannot Be Ignored
Anti-amyloid treatments also come with an important complication known as amyloid-related imaging abnormalities, or ARIA.
ARIA can involve swelling in the brain or small areas of bleeding.
Many cases may produce few or no obvious symptoms, but some can become serious.
Because of this risk, patients receiving drugs such as lecanemab require MRI monitoring. In 2025, the FDA recommended additional earlier MRI monitoring for patients taking Leqembi after reviewing safety information involving ARIA.
Risk can also differ according to genetics, particularly the APOE ε4 gene, which is associated with Alzheimer’s risk and can influence treatment safety decisions.
So this is not a medication that should be viewed like picking up a blood pressure prescription at the pharmacy.
Patient selection matters.
Brain imaging matters.
Diagnosis matters.
Genetics may matter.
And discussions between the patient, family and medical team matter.
But Something Even Bigger Is Happening: We Are Getting Better at Finding Alzheimer’s
Treatment gets most of the attention.
Diagnosis may turn out to be just as transformative.
Historically, establishing the biological presence of Alzheimer’s disease could involve expensive PET brain imaging or analysis of cerebrospinal fluid obtained through a lumbar puncture.
Now blood testing is becoming increasingly important.
In May 2025, the FDA cleared the first blood-based test designed to help identify amyloid pathology associated with Alzheimer’s disease in symptomatic patients age 55 and older. Research has focused heavily on markers such as phosphorylated tau, particularly p-tau217, which can correlate strongly with Alzheimer’s-related brain pathology.
This development could ultimately change the Alzheimer’s journey.
Instead of:
Memory trouble → years of uncertainty → extensive testing → diagnosis,
we may increasingly move toward:
Memory trouble → blood testing → confirmation → earlier treatment decision.
And research is going even further.
In March 2026, NIH highlighted work on an experimental blood-based “Alzheimer’s clock” being studied as a way of estimating when symptoms could emerge. The technology is still investigational, but it demonstrates how rapidly Alzheimer’s biomarker science is advancing.
This fits a much larger transformation in medicine we’ve discussed in The Age of Medical Discovery: medicine is gradually shifting from waiting until disease becomes obvious toward detecting biological changes much earlier.
Earlier Diagnosis Could Change the Entire Game
Why does earlier diagnosis matter so much?
Because many neurodegenerative diseases may have been developing for years before noticeable disability appears.
By the time extensive brain damage has occurred, removing one component of the disease may be too little, too late.
The future may therefore involve treating Alzheimer’s much earlier.
Think about heart disease.
Doctors don’t wait for your first heart attack before worrying about cholesterol, blood pressure or diabetes.
They try to identify risk before the catastrophe occurs.
Alzheimer’s medicine may eventually follow a similar path.
The goal could become:
Detect the disease early enough that significant cognitive decline never occurs—or occurs much later.
That’s a much bigger ambition than simply treating dementia after it becomes severe.
Amyloid May Not Be the Whole Story
For years, much of Alzheimer’s research concentrated heavily on beta-amyloid plaques.
The theory made sense.
Patients with Alzheimer’s often accumulate abnormal amyloid in their brains.
So remove the amyloid and perhaps the disease improves.
The reality has been more complicated.
Removing amyloid does not automatically restore lost memory.
That has forced researchers to investigate other contributors, including:
- Tau proteins
- Neuroinflammation
- Vascular disease
- Immune activity
- Synaptic damage
- Metabolic dysfunction
- Genetics
- Protein clearance systems within the brain
Alzheimer’s may ultimately prove to be less like one broken switch and more like an electrical panel with several circuits failing at once.
If that’s true, future treatment could resemble modern cancer therapy.
Not one Alzheimer’s drug.
A combination of treatments addressing different components of the disease at different stages.
A Fascinating New Target: Toxic Amyloid Oligomers
One particularly interesting idea involves not attacking the large amyloid plaques themselves, but targeting smaller forms of amyloid known as soluble amyloid-beta oligomers.
Researchers suspect these smaller protein clusters may be particularly damaging to neurons and synapses.
One experimental antibody pursuing this approach is PMN310, currently being studied in the PRECISE-AD trial.
Unlike plaque-targeting antibodies, PMN310 has been designed to preferentially target soluble toxic amyloid oligomers while minimizing binding to amyloid plaques.
In July 2026, ProMIS Neurosciences reported blinded six-month interim results from its Phase 1b trial. The company reported no cases of ARIA-E—brain swelling associated with ARIA—during that interim analysis and described early biomarker findings consistent with biological activity.
That is intriguing.
But here’s where discipline matters.
PMN310 remains an experimental treatment in an early-stage clinical trial.
Phase 1b results primarily tell researchers about safety, dosage and biological signals.
They do not prove that PMN310 prevents dementia or meaningfully preserves memory.
We need larger and longer studies before we know whether this approach works.
In other words:
Interesting? Absolutely.
Promising? Possibly.
Proven? No.
That’s exactly the distinction we have to maintain when discussing future medicine.
Tau May Become the Next Major Battlefield
Amyloid gets most of the headlines, but another abnormal protein called tau is increasingly important in Alzheimer’s research.
In a healthy brain, tau helps support structures inside nerve cells.
In Alzheimer’s disease, abnormal tau can form tangles associated with neuronal dysfunction and death.
Researchers are exploring antibodies, vaccines, small molecules and other approaches aimed at tau biology.
The likely future of Alzheimer’s treatment may therefore involve more than removing amyloid.
A patient could eventually receive one therapy addressing amyloid, another targeting tau, and perhaps additional treatments directed toward inflammation, vascular health or neuronal protection.
That would not be unusual in medicine.
We already treat hypertension with combinations of drugs.
Cancer treatments frequently involve multiple mechanisms.
HIV became manageable through combinations of antiviral therapies.
Alzheimer’s may eventually require the same type of multi-target thinking.
Prevention May Become as Important as Treatment
There is another part of the Alzheimer’s story that doesn’t involve futuristic pharmaceuticals at all.
Brain health and cardiovascular health overlap considerably.
Blood pressure, exercise, diabetes management, smoking, sleep, physical activity and social engagement all matter to healthy aging.
That does not mean someone can guarantee they will avoid Alzheimer’s by eating blueberries and walking around the block.
Biology doesn’t give guarantees.
But the broader lesson is important:
The future of Alzheimer’s may involve reducing risk long before anyone reaches the neurologist’s office.
That’s part of the philosophy behind Stay Healthy Until the Future Gets Here.
Medical science is advancing.
Our job is to remain as healthy and functional as possible while those advances continue arriving.
We Also Need to Stop Assuming Aging Means Dementia
There’s another misconception worth challenging.
Growing older does not automatically mean developing Alzheimer’s disease.
Memory changes can occur with normal aging, but dementia is not an inevitable consequence of having a lot of candles on your birthday cake.
That distinction matters psychologically.
We shouldn’t spend later life constantly waiting for Alzheimer’s to appear.
At the same time, significant or worsening memory changes should not simply be dismissed as:
“Oh, I’m getting old.”
Earlier evaluation is becoming increasingly valuable precisely because treatment and diagnostic options are improving.
The Next Twenty Years Could Look Very Different
Consider what has happened within only a few years.
We now have FDA-approved medications that can alter an underlying Alzheimer’s disease pathway.
Blood-based biomarker testing is becoming clinically useful.
Researchers are investigating oligomer-specific antibodies.
Tau-targeted therapies are advancing.
Genetic approaches are being investigated.
Clinical trials increasingly identify patients biologically rather than relying only on symptoms.
None of that guarantees a cure.
But compare that landscape with Alzheimer’s medicine twenty years ago.
The direction has clearly changed.
That’s why our broader discussion, Why the Next Twenty Years May Change Aging Forever, matters so much.
People in their 60s, 70s and 80s today may live through a period of medical development unlike anything previous generations experienced.
So Is This Real Progress or False Hope?
It’s real progress.
But hope needs a seat belt.
We should not tell families that Alzheimer’s has been solved.
It hasn’t.
Today’s approved disease-modifying treatments offer modest slowing of progression for selected people with early disease. They carry risks and require careful monitoring.
Blood tests are improving dramatically, but a positive biomarker does not automatically tell us exactly what will happen to a particular individual.
Experimental drugs like PMN310 are exciting, but early clinical trial results are not the same as proof of effectiveness.
And we still don’t know which combination of amyloid, tau, inflammation, vascular disease, genetics and other biological mechanisms will ultimately prove most important.
But compare that with where we were.
For decades the message was essentially:
We have Alzheimer’s disease, and we don’t know how to change its course.
Today the message is becoming:
We can see the disease earlier. We can measure its biology. We can target specific mechanisms. We can slow progression in some patients. And we’re learning how to attack it in entirely new ways.
That’s not a cure.
But it’s certainly not nothing.
The Future Is Arriving
Perhaps the most important lesson from modern medicine is that today’s incurable disease does not automatically remain tomorrow’s incurable disease.
Hepatitis C taught us that.
Some cancers are teaching us that.
Gene therapy is beginning to teach us that.
And Alzheimer’s research may be heading in the same direction.
The cavalry isn’t here yet.
But for the first time in a very long time, we can see movement over the hill.
For those of us growing older today, that’s a reason for optimism—but also a reason to stay informed, remain healthy and keep our expectations grounded in evidence.
Because the goal isn’t merely to live long enough to watch medical breakthroughs arrive.
It’s to stay healthy enough to benefit from them when they do.
The future of Alzheimer’s is no longer hopeless.
But the story is only beginning.
This article is for educational purposes and should not be considered medical advice. Anyone concerned about memory changes, Alzheimer’s disease or treatment eligibility should discuss evaluation and treatment options with a qualified healthcare professional.